International Progressive MS Alliance |

Positive phase III results for siponimod

Results presented at ECTRIMS show efficacy of siponimod in patients with secondary progressive MS

The Alliance now includes 16 MS organisations, all working together to speed up treatments for progressive MS

Sign up to our e-newsletter
for updates from our growing global initiative to end progressive MS

Clicking submit confirms that you consent to MSIF sending you the Progressive MS Alliance newsletter

Please note, you must be aged 18 or older to subscribe to our newsletters.